WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > EMQN (European Molecular Genetics Quality Network)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Research
Maxcyte, Inc. | August 12, 2021
MaxCyte, Inc., a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines. Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitle...
FUJIFILM Diosynth Biotechnologies | July 28, 2020
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...
Intravacc | August 18, 2020
Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...
Medical
AvantGen | January 12, 2021
AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...
MedTech, Medical
Video
Industrial Impact
Whitepaper
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE